Ambergen
Watertown, US · Founded 2022 · Delaware corporation
Find your way into Ambergen
Sign up to see every warm intro you have to Ambergen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ambergen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AmberGen operates the MaxOmic Laboratory, offering multiomic spatial biology imaging and analysis services along with probes, panels, and antibody conjugation kits based on its patented photocleavable mass-tag technology. It serves researchers, drug developers, and clinicians in the life sciences and biotech sector.
Founders & leadership
Ambergen was founded in 2022 by Kenneth Rothschild.

Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2022
▶$5MraisedApr 2022 · 1 investors · BiotechnologyRule 506(b)
- Michael EasterlingDirector
- Kenneth RothschildExecutive Officer, Director
- John GillespieExecutive Officer, Director
- Peter FinnExecutive Officer
- Brian RothschildDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 50+ SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $999.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $698.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $596.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $199.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $188.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $187.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2008 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $848.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $657.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $383.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $381.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $749.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $749K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $187.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $154.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $187.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $183.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2004 | $749.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $599.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $187K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $121.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $599.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $599.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $99.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2001 | $549.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2001 | $388.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | $98.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2000 | $372.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Ambergen do?
- AmberGen operates the MaxOmic Laboratory, offering multiomic spatial biology imaging and analysis services along with probes, panels, and antibody conjugation kits based on its patented photocleavable mass-tag technology. It serves researchers, drug developers, and clinicians in the life sciences and biotech sector.
- Who founded Ambergen?
- Ambergen was founded by Kenneth Rothschild in 2022.
- How much funding has Ambergen raised?
- Ambergen has disclosed $5M raised across 1 round.
- Where is Ambergen headquartered?
- Ambergen is headquartered in Watertown, US.
